Skip to main content
ENSC logo

Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis

Ensysce Biosciences, Inc. (ENSC) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.3699 (-4.91%), as of the Nov 18, 2026 trading session; market cap $7.20M.

Educational signal · not a buy or sell recommendation · How to read this

$0.3699 −$0.0191 (-4.91%) Market Cap $7.20M

Ensysce Biosciences, Inc. · ENSC · NASDAQ

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies. Their primary focus is on creating abuse-resistant and overdose-resistant opioid prodrugs.

Price as of Nov 18, 2026

Key Statistics

20 of 100

MoonshotScore v2 · Ensysce Biosciences (ENSC)

Weak
Business Quality Poor (11)
Financial Safety Strained (37)
Valuation Fair (68)
Growth Durability Shrinking (10)
Momentum Quiet (44)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, a strained balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Quiet.

  • EPS beat 0 of the last 4 reports
  • Altman Z -9.15 · Piotroski F 4

Holding back: weak fundamentals, soft growth

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ENSC (57 recorded, newest six shown)
RecordedScoreBand
19Weak
18Weak
19Weak
19Weak
20Weak
20Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.3699
Change on the day-4.91%
52-week range$0.23 – $2.16
Market capitalisation$7.20M—
Price / earnings (trailing)-0.22
Shares traded on the day130.0K

Price & events

Other perspectives

Council score for Ensysce Biosciences (ENSC): perspectives

Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.

5-Factor Breakdown

Business Quality Negative
Financial Safety Weak
Valuation Moderate
Growth Durability Negative
Momentum Neutral

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Negative
Gross Margin Neutral

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ensysce Biosciences (ENSC), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ensysce Biosciences, Inc. (ENSC) is listed on NASDAQ. It employs 9 people and is led by D. Lynn Kirkpatrick. The market values it at $7.20M.

2 · Latest results

What do the latest results show for Ensysce Biosciences (ENSC)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$2M-$82M-$4.51 (diluted)
Q2 FY2026$1M-$3M-$0.20 (diluted)
Q1 FY2026$0-$4M-$0.52 (diluted)
Q4 FY2025$2M-$3M-$0.11 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ensysce Biosciences (ENSC)?

Short answer · as of

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z -9.15 · Piotroski F 4. Trailing ratios: current ratio 8.02.

Data-derived red flags

  • Listing risk — at $0.3699 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of -9.15 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
5 · Peer comparison

How does Ensysce Biosciences compare with its peers?

Short answer

Ensysce Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Pharming Group N.V. (PHAR) Same industry, near in market value$12.48 Nov 18, 2026$884M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
Indaptus Therapeutics, Inc. (INDP) Same industry, near in market value$3.29 Nov 18, 2026$505M60 5-pillar Nov 18, 2026
Ensysce Biosciences (ENSC) — this page$0.3699$7.20M20

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Most recent available transactions

Transactions
12
Identified insiders
4
Purchases
6
Sales
0
Other transactions
6

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ENSC in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ENSC in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ensysce Biosciences (ENSC)?

Read these with our analysis →

Ensysce Biosciences Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ENSC research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ENSC?

ENSC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies.

Is ENSC a good stock to buy?

Stock Expert AI does not rate ENSC buy, sell or hold. Ensysce Biosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ENSC stock price today?

The last price recorded for Ensysce Biosciences, Inc. (ENSC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ENSC?

The main risks for Ensysce Biosciences, Inc. include the inherent risks associated with clinical-stage pharmaceutical companies, such as the possibility of unsuccessful clinical trial outcomes and failure to obtain regulatory approval from the FDA. The company's high cash burn rate and dependence on securing additional funding also pose financial risks.

What are the key factors to evaluate for ENSC?

Ensysce Biosciences, Inc. (ENSC) holds a MoonshotScore in the low range. Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-resistant and overdose-resistant opioid prodrugs. Not financial advice.

How frequently does ENSC data refresh on this page?

ENSC's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ENSC's recent stock price performance?

Ensysce Biosciences, Inc. (ENSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative TAAP and MPAR technology platforms. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ENSC overvalued or undervalued right now?

Ensysce Biosciences, Inc. (ENSC) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ENSC?

Fractional-share availability for Ensysce Biosciences, Inc. (ENSC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.